{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:27:22Z","timestamp":1762475242980,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jdcr.2020.12.011","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T06:06:58Z","timestamp":1608271618000},"page":"77-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Infusion reaction to infliximab biosimilar after transitioning from infliximab"],"prefix":"10.1016","volume":"8","author":[{"given":"Reem","family":"Kashlan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis B.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Narla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2020.12.011_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"10086","key":"10.1016\/j.jdcr.2020.12.011_bib2","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from\u00a0originator infliximab to biosimilar CT-P13 compared with\u00a0maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jdcr.2020.12.011_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jdcr.2020.12.011_bib4","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jdcr.2020.12.011_bib5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.jdcr.2020.12.011_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14740338.2017.1323330","article-title":"Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort","volume":"16","author":"Balint","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.jdcr.2020.12.011_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-017-0693-5","article-title":"Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview","volume":"77","author":"Hindryckx","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jdcr.2020.12.011_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2019.00601","article-title":"Evaluation of in\u00a0vitro assays to assess the modulation of dendritic cells functions by therapeutic antibodies and aggregates","volume":"10","author":"Morgan","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jdcr.2020.12.011_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3343\/alm.2020.40.2.101","article-title":"Laboratory monitoring of biological therapies in rheumatology: the role of immunogenicity","volume":"40","author":"Benucci","year":"2020","journal-title":"Ann Lab Med"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512620308584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512620308584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:22:38Z","timestamp":1762474958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512620308584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":9,"alternative-id":["S2352512620308584"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.011","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infusion reaction to infliximab biosimilar after transitioning from infliximab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}